Aditxt subsidiary Pearsanta receives IRB approval to begin clinical studies for endometriosis blood test

Aditxt, Inc.

Pearsanta received IRB approval to start clinical studies for a blood-based diagnostic test for endometriosis using mitochondrial DNA analysis.
Test uses Mitomic technology to detect disruptions in mitochondrial DNA from a blood sample; aims to replace invasive laparoscopic diagnosis.
Clinical validation targets ~100 samples from OB-GYN sites; commercial launch as an LDT targeted for end of June 2025.
Next test in pipeline is for prostate cancer; Richmond CLIA/CAP lab to process samples.
Collaborating with Evofem to recruit OB-GYN sites for the study; highlights synergies between subsidiaries.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.